Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;41(12):3423-3435.
doi: 10.1007/s10072-020-04837-0. Epub 2020 Oct 20.

Update on cerebrovascular manifestations of COVID-19

Affiliations
Review

Update on cerebrovascular manifestations of COVID-19

Reza Naeimi et al. Neurol Sci. 2020 Dec.

Abstract

The novel member of coronaviruses family, severe acute respiratory coronavirus-2 (SARS-CoV-2), with high structural homology to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS) has spread rapidly with about 20 million cases infection and over 700,000 deaths. SARS-CoV-2 has been emerged as a worldwide disaster due to non-specific few respiratory and gastrointestinal manifestations at the onset of disease as well as long incubation period. Surprisingly, not only respiratory failure but also the underlying coagulation disorder and neurovascular involvement worsen the clinical outcome of infected patients. In this review article, we describe the probable mechanisms of SARS-CoV-2 infection and stroke occurrence. We will also discuss the cerebrovascular events following SARS-CoV-2 infection, the recommended therapies, and future prospects to better manage these patients in coronavirus disease 2019 (COVID-19) outbreak.

Keywords: Anticoagulative therapies; COVID-19; Coagulation; Coronavirus; SARS-CoV-2; Stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Lung alveolus in phases I and II. SARS-CoV-2 enters into type II alveolar epithelial cells via TMPRSS2 or ACE2 receptors. After viral replication and proliferation, immune response is initiated by monocytes, macrophages, and neutrophils. Then at phase III, inflammatory cytokines such as IL-2, 6, 7, TNF-α, and IFN-γ induce the cytokine storm and systemic inflammation. Lung parenchymal injury is occurred following inflammatory processes, vasodilation, endothelial permeability, leukocyte recruitment, and pulmonary edema. Lung vascular endothelium destruction by direct SARS-CoV-2 entrance and induced inflammation can predispose microthrombus formation and lung infarction
Fig. 2
Fig. 2
SARS-CoV-2 directly induces the endothelial cell death in the blood-brain barrier (BBB). The tight junctions in endothelial cells are destructed through monocytes, neutrophils, IL-1β, and TNF-α. In addition to underlying coagulopathy, the basement membrane and Von-Willebrand factor (VWF) contiguity with platelets and RBCs facilitate thrombus formation. The developed thrombus in the brain or other origins such as cardiac thrombus or deep vein thrombus can potentially embolize to distal parts or other branches. Hypoxia-induced vasodilation besides endothelial damage makes the possibility of SARS-CoV-2 dissemination to brain parenchyma or cerebrospinal fluid. High thrombin level due to low protein C, antithrombin III, and tissue factor pathway inhibitor amplifies the function of proteinase-activated inhibitor 1 (PAR-1) receptors which is led to inflammation. AT-III, antithrombin III; Pro C, protein c; TFI, tissue factor pathway inhibitor

Similar articles

Cited by

References

    1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. doi: 10.1016/S0140-6736(20)30185-9. - DOI - PMC - PubMed
    1. Organization, W.H., WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. 2020
    1. Jin H et al (2020) Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc. Neurol:svn-2020–sv000382 - PMC - PubMed
    1. Dalan R, Bornstein SR, el-Armouche A, Rodionov RN, Markov A, Wielockx B, Beuschlein F, Boehm BO. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020;52(5):257–263. doi: 10.1055/a-1155-0501. - DOI - PMC - PubMed
    1. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li D, Li J, Lian H, Niu S, Zhang L, Zhang J. Characteristics of COVID-19 infection in Beijing. J Inf Secur. 2020;80:401–406. - PMC - PubMed

LinkOut - more resources